EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors by White, Robert E et al.








EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized
mice and is found in human tumors
White, Robert E; Rämer, Patrick C; Naresh, Kikkeri N; Meixlsperger, Sonja; Pinaud, Laurie; Rooney,
Cliona; Savoldo, Barbara; Coutinho, Rita; Bödör, Csaba; Gribben, John; Ibrahim, Hazem A; Bower,
Mark; Nourse, Jamie P; Gandhi, Maher K; Middeldorp, Jaap; Cader, Fathima Z; Murray, Paul; Münz,
Christian; Allday, Martin J
Abstract: Epstein-Barr virus (EBV) persistently infects more than 90% of the human population and
is etiologically linked to several B cell malignancies, including Burkitt lymphoma (BL), Hodgkin lym-
phoma (HL), and diffuse large B cell lymphoma (DLBCL). Despite its growth transforming properties,
most immune-competent individuals control EBV infection throughout their lives. EBV encodes various
oncogenes, and of the 6 latency-associated EBV-encoded nuclear antigens, only EBNA3B is completely
dispensable for B cell transformation in vitro. Here, we report that infection with EBV lacking EBNA3B
leads to aggressive, immune-evading monomorphic DLBCL-like tumors in NOD/SCID/￿c-/- mice with re-
constituted human immune system components. Infection with EBNA3B-knockout EBV (EBNA3BKO)
induced expansion of EBV-specific T cells that failed to infiltrate the tumors. EBNA3BKO-infected B
cells expanded more rapidly and secreted less T cell-chemoattractant CXCL10, reducing T cell recruit-
ment in vitro and T cell-mediated killing in vivo. B cell lines from 2 EBV-positive human lymphomas
encoding truncated EBNA3B exhibited gene expression profiles and phenotypic characteristics similar to
those of tumor-derived lines from the humanized mice, including reduced CXCL10 secretion. Screening
EBV-positive DLBCL, HL, and BL human samples identified additional EBNA3B mutations. Thus,
EBNA3B is a virus-encoded tumor suppressor whose inactivation promotes immune evasion and virus-
driven lymphomagenesis.
DOI: 10.1172/JCI58092




White, Robert E; Rämer, Patrick C; Naresh, Kikkeri N; Meixlsperger, Sonja; Pinaud, Laurie; Rooney,
Cliona; Savoldo, Barbara; Coutinho, Rita; Bödör, Csaba; Gribben, John; Ibrahim, Hazem A; Bower,
Mark; Nourse, Jamie P; Gandhi, Maher K; Middeldorp, Jaap; Cader, Fathima Z; Murray, Paul; Münz,
Christian; Allday, Martin J (2012). EBNA3B-deficient EBV promotes B cell lymphomagenesis in hu-
manized mice and is found in human tumors. Journal of Clinical Investigation, 122(4):1487-1502. DOI:
10.1172/JCI58092
Research article
	 The	Journal	of	Clinical	Investigation      http://www.jci.org  
EBNA3B-deficient EBV promotes B cell 
lymphomagenesis in humanized mice  
and is found in human tumors
Robert E. White,1 Patrick C. Rämer,2 Kikkeri N. Naresh,3 Sonja Meixlsperger,2 Laurie Pinaud,1 
Cliona Rooney,4 Barbara Savoldo,4 Rita Coutinho,5 Csaba Bödör,5 John Gribben,5  
Hazem A. Ibrahim,3 Mark Bower,6 Jamie P. Nourse,7 Maher K. Gandhi,7 Jaap Middeldorp,8  
Fathima Z. Cader,9 Paul Murray,9 Christian Münz,2 and Martin J. Allday1
1Section of Virology, Faculty of Medicine, Imperial College London, London, United Kingdom. 2Viral Immunobiology, Institute of Experimental Immunology, 
University of Zürich, Zürich, Switzerland. 3Department of Histopathology, Hammersmith Hospital Campus, Imperial College Healthcare NHS Trust, London, 
United Kingdom. 4Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, USA. 5Centre of Haemato-Oncology, Barts Cancer Institute, 
Queen Mary University of London, London, United Kingdom. 6Department of Medical Oncology, Chelsea and Westminster Hospital, London, United Kingdom. 
7Clinical Immunohaematology, Queensland Institute of Medical Research, Brisbane, Queensland, Australia. 8Department of Pathology,  
VU University Medical Centre, Amsterdam, The Netherlands. 9School of Cancer Sciences, College of Medical and Dental Sciences,  


























































































EBNA3BKO is more tumorigenic than wild-type EBV in mice reconsti-


















































































EBNA3BKO cell lines derived from huNSG mice resemble in vitro–gen-





























EBNA3BKO infection of mice with reconstituted human immune system components leads to splenomegaly and tumor formation. (A) Recon-
stitution levels of human lymphocytes in mice used to study in vivo biology of EBNA3BKO (n = 66). Frequencies of human lymphocytes in 
peripheral blood of mice were determined by flow cytometry. Reconstitution levels for each animal are provided in Supplemental Table 1. (B) 
Macroscopically visible tumors (arrows) in spleens of animals 28 days after infection with PBS, wtBAC, EBNA3Brev, or EBNA3BKO by i.p. 
injection. Scale bars: 1 cm. (C) Frequency of overt tumor formation 28 days after infection. (D) Spleen/body weight ratio 28 days after infection. 
Data points represent individual mice; horizontal bars represent means. Shown is 1 representative of 3 experiments (B and D) or pooled data 
from 3 experiments (C).
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Histological and immunohistochemical fea-
tures of splenic lesions in EBNA3BKO-, 
EBNA3Brev-, and wtBAC-infected mice. 
Shown are H&E and immunohistochemical 
sections from representative spleens of 
wtBAC- and EBNA3Brev-infected mice com-
pared with a tumor from an EBNA3BKO-
infected mouse. Original magnification, 
×200. (A) EBER-1 in situ hybridization, 
showing EBV-positive cells. (B) H&E images 
showing monomorphic expansion of sheets 
of large lymphoid cells in the EBNA3BKO 
tumor — distinct from the polymorphic cellu-
lar composition of the splenic lesions (wtBAC 
and EBNA3Brev) — composed of a mix of 
lymphoid cells of varying sizes, plasma cells, 
and histiocytes. (C) Immunostaining for B 
cells (CD20). Nearly 100% of the cells in 
the EBNA3BKO-induced tumor were large B 
cells, whereas B cells of varying sizes repre-
sent approximately 40% of the cells in wtBAC- 
and EBNA3Brev-infected spleens. (D) 
Immunostaining for cell proliferation (Ki67). 
More than 95% of cells in the EBNA3BKO-
induced tumor proliferated, versus approxi-
mately 40% in wtBAC- and EBNA3Brev-
infected spleens. (E) Immunostaining for 
T cells (CD3). Only sparse infiltrating T cells 
were observed in the EBNA3BKO-induced 
tumor, whereas at least 50% of the cells in 
wtBAC- and EBNA3Brev-infected splenic 
lesions were T cells.
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Transformation of B cells in vitro using EBNA3BKO is more efficient, and ex vivo–expanded tumor cells lacking EBNA3B show enhanced tumori-
genicity, in unreconstituted NSG mice. (A) CFSE-labeled PBMCs from healthy donors were infected with EBV (2.5 × 104 RGU per 106 PBMCs). 
CFSE dilution as a surrogate of proliferation was measured over a period of 14 days. Pooled data from 6 healthy donors are shown. 2 LCLs from 
each of the 6 donors were assessed at the indicated time points. Data are mean ± SD. (B) Frequency of successful outgrowth of NSG-LCLs from 
spleens of animals infected with 104 RGU of EBV. Pooled data from 3 experiments are shown. (C) Growth behavior of NSG-LCLs was assessed 
longitudinally. 5 × 105 NSG-LCLs/ml were seeded, and cell numbers were determined at the indicated times. Data are mean ± SD. (D) 20 days 
after i.p. injection of 107 ex vivo–expanded tumor cells into immunodeficient NSG mice, spleens were weighed relative to total animal mass to 
assess splenomegaly. 1 representative of 2 experiments is shown. Statistical significance was assessed using unpaired Student’s t test. (E) 
Splenic DNA from animals injected with EBV-transformed tumor cells was isolated 20 days after injection, and EBV DNA load was determined 
by qPCR. 1 representative of 2 experiments is shown. (D and E) Data points represent individual mice; horizontal bars represent means.
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Table 
Summary of potential EBNA3B mutations in B cell tumors
Tumor	 EBV	 Tumor	 Immunosuppression	 Presenting	location	 Potential	EBNA3B	mutations/unique	polymorphismsA	
identifier	 type	 type	 	 (ethnicity)
	 	 	 	 	 Missense	and	nonsenseB	 ConservativeC	 NoncodingD
TRL1 1 PTLDE IS USA (European descent) 245	bp	deletion   
     (E366-F448), V559F
TRL595 1 PTLDF IS USA (Hispanic) G	insertion	at	D195  
DLBCL-3 1 DLBCLG None UK (European descent) R8K  
ABC-1B 1 ABC-DLBCL None UK (European descent)   
ABC-4 1 ABC-DLBCL IS UK (Chinese)  –110 (TG→TA)
ABC-D17 1 ABC-DLBCL None UK (NA)  G648 
ABC-DL04 1 ABC-DLBCL None Australia (European descent)   
ABC-H9 1 ABC-DLBCL HIV UK (NA) A682P, W689C  
ABC-P8 1 ABC-DLBCL IS UK (NA) P87T  
ABC-PDL10 1 ABC-DLBCL IS Australia (European descent) R92H, P609R  
ABC-H31 2 ABC-DLBCL HIV UK (NA)   
ABC-H7 2 ABC-DLBCL HIV UK (NA) G263STOP G287 
ABC-DL67 1 ABC-DLBCL None Australia (Polynesian) E43D, I44N, S59A, E64, N183, Q601 –110 (TG→CA),  
     G83Y, T91S, T212P,  –35 (G→A), 
     A425T, V559L, Q575H  intron1+46(ins-T)H
GC-7a 1 GC-DLBCL HIV UK (Nigerian)   
GC-DL29 1 GC-DLBCL None Australia (European descent)   
GC-DL44 1 GC-DLBCL None Australia (European descent)   
GC-H23 1 GC-DLBCL HIV UK (NA)   
GC-H25 1 GC-DLBCL HIV UK (NA) Q29R  
GC-PDL5 1 GC-DLBCL IS Australia (European descent)   
GC-H13 2 GC-DLBCL HIV UK (NA)   
HL01 1 HL NA UK (NA)   
HL02 1 HL NA UK (NA) P441L  
HL03 1 HL NA UK (NA)   
HL04 1 HL NA UK (NA) T103M  
HL05 1 HL NA UK (NA)   
HL06 1 HL NA UK (NA)   
HL07 1 HL NA UK (NA)  L628 
HL08 1 HL NA UK (NA) PRAT441-4L   
     (9 bp deletion)
HL09 1 HL NA UK (NA) E462K  
HL10 1 HL NA UK (NA)   
HL11 1 HL NA UK (NA) G503S  
BL#9I 1 BL NA Uganda (NA)   
BL#27I 1 BL NA Uganda (NA)   
BL#31I 1 BL NA Uganda (NA) Q461del   
     (3 bp deletion)
BL#61I 1 BL NA Uganda (NA)   
BL#63I 1 BL NA Uganda (NA)   
BL#64I 1 BL NA Uganda (NA)   
BL#74I 1 BL NA Uganda (NA)   –98A→C
BL#204I 1 BL NA Uganda (NA)   
BL#217I 1 BL NA Uganda (NA)   intron1+46(ins-T)H
BL#248I 1 BL NA Uganda (NA)  D359 
LCL sequence was confirmed in primary tumor material (26). Excepting the TRL595 sequence (from a tumor-derived LCL), all others are from sequencing 
of tumor DNA. HIV, HIV-positive patient; IS, undergoing immunosuppressive therapy to prevent transplant rejection; None, no immunosuppression; NA, 
information not available. AAnalysis covered only the region of EBNA3B from 190 bp upstream of the start codon to amino acid 700 of the coding region. 
Potential mutations were defined as sequence variations that occurred in only 1 of the 41 tumor-derived or 75 LCL DNA sequences analyzed. BPotential 
mutations that changed the amino acid sequence of the protein (missense) or introduce a premature termination codon (nonsense; bold). CBase changes 
that did not alter the protein coding sequence. DChanges outside the amino acid coding region, expressed relative to the translational start (A of ATG is 
position 0) or within intron 1 (first base of the intron is position +1). EDLBCL. FFollicular hyperplasia. GUnclassified DLBCL subtype. HThese 2 insertions 
(changing 7 consecutive T residues to 8) are the same, but are included as potential mutations as they occurred in 2 clearly distinct genetic backgrounds 
(Supplemental Figure 5C). IDescribed in detail previously (53).
research article


























































































































	 The	Journal	of	Clinical	Investigation      http://www.jci.org
research article














partially  impaired  in  the EBNA3BKO-LV[CXCL10]-LCLs.  In 



















































































PTLD-derived LCLs lacking EBNA3B phenotypically resemble those 
derived from infected mice. (A) Relative gene expression levels, mea-
sured by qPCR using Taqman low-density arrays, normalized against 
4 endogenous controls, and plotted on a log2 scale as the distance 
from the geometric mean expression for that gene across all cell lines. 
Data are mean ± SEM for the EBNA3BKO and combined wtBAC and 
EBNA3Brev cell lines. Also shown are expression levels in the patient-
derived cell lines, for which error bars indicate expression values of 
the 2 TRL1 lines. Data points are connected to clarify data trends. (B) 
Flow cytometry profiles for LAIR1 and CD11a expression in ex vivo–
expanded cells from 2 mouse experiments and EBNA3B mutant PTLD 
patients (ptLCLs). Each plot contains the same number of gated events 
to facilitate comparison of samples within the same experiment. (C) 
Principal component correlation analysis of cell lines based on gene 
expression data from qPCR analysis of the 48 genes shown in Supple-
mental Figure 3. Samples are identified by the infecting virus (color) 
and whether the LCLs were established in vitro or ex vivo (shape). 
Groups by virus and LCL type are indicated by overlaid icosahedrons 
colored by virus type; wtBAC and EBNA3Brev were considered as a 
single group, and TRL1 and TRL595 lines were separated. Percent 
contribution of each principal component to total variation is indicated 
on the respective axis.
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EBNA3B mutations identified in lymphomas. Schematic representation (to scale) of the EBNA3B gene locus (flanked by EBNA3A and EBNA3C 
as indicated) and, below, visual representation of definite and potential EBNA3B mutations (i.e., tumor-only polymorphisms) identified by com-
paring 39 lymphoma samples with 69 sLCLs. Only those samples with at least 1 possible mutation are shown. Bold horizontal lines indicate 
the coding region analyzed for mutations (amino acids 1–700). Dashed horizontal lines indicate the extent of sequence used in the sequence 
alignment (see Supplemental Data File 1). EBNA3B mutations identified in LCLs grown from PTLD tumors (i.e., TRL1 and TRL595) are shown 
for comparison. Red symbols, mutations leading to a premature STOP codon; blue symbols, potential missense mutations; green symbols, DNA 
changes that do not alter protein sequence. Vertical lines represent substitution mutants/polymorphisms; inverted triangles indicate insertional 
mutations; and deletion mutants are shown by open triangles, with the associated box indicating the deletion size. Sample ABC-H7 (bold) con-
tains a truncation mutation (GGA to TGA substitution mutant at codon 263) positioned between the 2 previously described TRL mutants. See 
Table 1 for details of these mutations and characteristics of all tumors analyzed.
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Infection with EBNA3BKO primes stronger immune responses than infection with wtBAC or EBNA3Brev. Splenocytes from control or EBV-
infected animals were isolated 28 days after infection. (A) CD3+ T cell frequency among human CD45+ lymphocytes, determined by flow cytom-
etry. (B) Ratio of CD8+ T cell to CD4+ T cell frequency. (C) Activation of T cells, assessed by HLA-DR expression on their surface. (D) Isolated 
splenocytes were depleted of human B cells and cocultured with ex vivo–expanded tumor cell lines to measure EBV-specific IFN-γ secretion, 
determined using ELISPOT assays and expressed as the number of IFN-γ–specific spots per 2 × 105 cells. Pooled data from 2 experiments are 
shown. (A–D) Data points represent individual mice; horizontal bars represent means.
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Figure 
EBNA3BKO-transformed tumor cells produce and secrete reduced amounts of CXCL10 and attract fewer EBV-specific T cells. (A) CXCL10 
mRNA levels, determined by qPCR, normalized to GAPDH expression, and expressed relative to CXCL10 expression of wtBAC-transformed 
tumor cells. (B) CXCL10 protein levels, determined in culture supernatants of EBV-transformed tumor cells by ELISA after 24 hours of culture 
with or without added IFN-γ. (C) Migration of the EBV-specific CD8+ T cell clone MS.B11 toward tumor cell–conditioned supernatants, assessed 
by Transwell migration assay. For EBNA3BKO-transformed tumor lines and patient PTLD LCLs, CXCL10 was supplemented as indicated 
to reach concentrations present in wtBAC- and EBNA3Brev-conditioned supernatants. (A–C) Shown is 1 representative of 2 experiments 
with 2 wtBAC, 3 EBNA3Brev, 7 EBNA3BKO, and 2 patient PTLD LCLs (TRL1-post and TRL595). (D and E) Killing of CXCL10-reexpressing 
EBNA3BKO LCLs by an autologous T cells line was tested in vivo. LCLs were transduced with a CXCL10-expressing lentivirus or control virus. 
In vivo killing assays were performed after labeling of LCLs with PKH26 and high or low concentration of CFSE. (D) Example of FACS gating for 
the experiment, and representative histograms for tumor cell composition before and after injection in the presence or absence of autologous T 
cells. Percentages denote CXCL10+ and CXCL10– cells as a fraction of total tumor cells. (E) Summary of 3 experiments performed as described 
in D. (A–E) Data are mean ± SD.
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In vitro killing assay. In vitro killing assays were performed as previously 
described (50), with minor modifications. Target cells (LCLs) were stained 
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In vivo killing assay. For in vivo killing assays, EBNA3BKO-LV[CXCL10]-








































qPCR for gene expression. CXCL10 mRNA quantitation (Figure 7A) was 





























































































































Address  correspondence  to: Martin  Allday,  Section  of  Virol-


































  9. Vereide  DT,  Sugden  B.  Lymphomas  differ  in 











Natl Acad Sci U S A. 2011;108(5):1919–1924.





























  19. Münz C,  et  al. Human CD4(+) T  lymphocytes 
consistently  respond  to  the  latent  Epstein-
Barr  virus  nuclear  antigen  EBNA1.  J Exp Med. 
2000;191(10):1649–1660.
  20. Leen  A,  et  al.  Differential  immunogenic-
ity  of  Epstein-Barr  virus  latent-cycle  proteins 
for human CD4(+) T-helper 1 responses. J Virol. 
2001;75(18):8649–8659.




  22. Ishikawa  F,  et  al.  Development  of  functional 
human  blood  and  immune  systems  in  NOD/





















































































kin’s  disease:  transcriptional  analysis  of  virus 
latency in the malignant cells. J Exp Med. 1993; 
177(2):339–349.
































express killer  cell  Ig-like  receptors and become 
cytolytic. J Immunol. 2004;172(3):1455–1462.
  51. Smith CA, et al. Production of genetically modi-
fied Epstein-Barr virus-specific cytotoxic T cells for 
adoptive transfer to patients at high risk of EBV-
associated lymphoproliferative disease. J Hemato-
ther. 1995;4(2):73–79.
  52. Spies T, et al. A gene in the human major histo-
compatibility complex class II region controlling 
the class I antigen presentation pathway. Nature. 
1990;348(6303):744–747.
  53. Paschos K, Smith P, Anderton E, Middeldorp JM, 
White RE, Allday MJ. Epstein-Barr virus latency 
in B cells leads to epigenetic repression and CpG 
methylation of the tumour suppressor gene Bim. 
PLoS Pathog. 2009;5(6):e1000492.
  54. van Dongen JJM, et al. Design and standardiza-
tion of PCR primers and protocols for detection of 
clonal immunoglobulin and T-cell receptor gene 
recombinations in suspect lymphoproliferations: 
report of the BIOMED-2 Concerted Action BMH4-
CT98-3936. Leukemia. 2003;17(12):2257–2317.
  55. Sample J, et al. Epstein-Barr virus types 1 and 2 
differ in their EBNA-3A, EBNA-3B, and EBNA-3C 
genes. J Virol. 1990;64(9):4084–4092.
  56. Tamura K, Peterson D, Peterson N, Stecher G, 
Nei M, Kumar S. MEGA5: molecular evolution-
ary genetics analysis using maximum likelihood, 
evolutionary distance, and maximum parsimony 
methods. Mol Biol Evol. 2011;28(10):2731–2739.
